SCHEMBL5857433

SCHEMBL5857433

CC(=O)N(CCCN(C)C)c1ccc(NC(=C2C(=O)Nc3cc(Cl)ccc32)c2ccc3nccnc3c2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 7/20 0.35
LCK P06239 2/20 0.34
RAB9A P51151 4/20 0.34
NPC1 O15118 3/20 0.34
KMT2A Q03164 1/20 0.34
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GAA P10253 1/20 0.33
PLK3 Q9H4B4 6/20 0.33
PDGFRB P09619 5/20 0.33
KDR P35968 5/20 0.33
LIMK1 P53667 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
RPS6KA2 Q15349 2/20 0.33
RPS6KA3 P51812 1/20 0.33
TP53 P04637 1/20 0.33
KIT P10721 2/20 0.32
FGFR1 P11362 2/20 0.32
FLT3 P36888 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3935373 1.00 PLK1 (0.35) PLK1LCKRAB9ANPC1KMT2A
SCHEMBL5859511 0.92 HTT (0.38) PLK1LCKRAB9ANPC1MAPT
SCHEMBL3944370 0.92 HTT (0.38) PLK1LCKRAB9ANPC1MAPT
SCHEMBL3932538 0.91 PLK1 (0.36) PLK1LCKRAB9ANPC1KMT2A
SCHEMBL5858545 0.91 PLK1 (0.36) PLK1LCKRAB9ANPC1KMT2A
SCHEMBL5857172 0.91 FLT3 (0.36) LCKRAB9ANPC1KMT2AMAPT
SCHEMBL3937720 0.91 FLT3 (0.36) LCKRAB9ANPC1KMT2AMAPT
SCHEMBL3934975 0.91 MAPT (0.36) LCKRAB9ANPC1KMT2AMAPT
SCHEMBL5856823 0.91 MAPT (0.36) LCKRAB9ANPC1KMT2AMAPT
SCHEMBL225449 0.90 LRRK2 (0.36) PLK1LCKRAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 PLK1 86/4885LCK 79/4885RAB9A 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.